Vaccine Doubts Hit Sentiment
Thursday’s session was quiet owing to most traders sitting on their hands given the Thanksgiving holiday in the US. Whilst the US markets are open for a half day, we’re not expecting much in the way of volume. Black Friday shopping is also offering another distraction.
Share this:
Thursday’s session was quiet owing to most traders sitting on their hands given the Thanksgiving holiday in the US. Whilst the US markets are open for a half day, we’re not expecting much in the way of volume. Black Friday shopping is also offering another distraction.
European bourses are edging lower, as the vaccine optimism seen at the start of the week has completely fizzled now that questions are growing over the soundness of the AstraZeneca covid vaccine trial. The doubts could delay the cheap and easily transported vaccine from being approved quickly by regulators.
The pharmaceutical giant is likely to run a new additional study to assess the efficacy of a lower dosage after a subgroup which accidentally received an initial half dose revealed the dose to be 90% effective. AstraZeneca share are trading 1% lower.
Chinese factory profits soar
Concerns over the vaccine are overshadowing news that Chinese industrial profits surged at the fastest pace since early 2017. Although the minrers are finding support from the knowledge that the recovery in the world’s largest consumer of metals was powering along nicely. This is a stark contrast to Europe and the US which are still battling to bring covid infections under control.
Concerns over the vaccine are overshadowing news that Chinese industrial profits surged at the fastest pace since early 2017. Although the minrers are finding support from the knowledge that the recovery in the world’s largest consumer of metals was powering along nicely. This is a stark contrast to Europe and the US which are still battling to bring covid infections under control.
UK’s gloomy outlook
The British government yesterday announced the UK Tier breakdown for when the national lockdown ends next week. With around 20 million Brits going from national lockdown to Tier 3, the toughest category the economic outlook for the UK remains particularly gloomy
The British government yesterday announced the UK Tier breakdown for when the national lockdown ends next week. With around 20 million Brits going from national lockdown to Tier 3, the toughest category the economic outlook for the UK remains particularly gloomy
Oil & gold struggle
Oil prices are declining on Friday in quiet trade amid concerns over oversupply and doubts over a vaccine to end the covid pandemic. Despite falling for a second straight session both Brent and WTI are on track to book gains in the region of 6% across the week.
Meanwhile, the risk off mood wasn’t helping gold, which continues to struggle for direction just north of $1800.
Oil prices are declining on Friday in quiet trade amid concerns over oversupply and doubts over a vaccine to end the covid pandemic. Despite falling for a second straight session both Brent and WTI are on track to book gains in the region of 6% across the week.
Meanwhile, the risk off mood wasn’t helping gold, which continues to struggle for direction just north of $1800.
FTSE Chart
After the FTSE’s strong run up at the start of the month on vaccine news, the rally has been consolidating in the horizontal channel of 6515 and 6325. The price is currently find support on the lower ban of the channel. A break through 6325 could open the door to a deeper selloff towards horizontal support at 6120 and then near 6000, the confluence of the 50,100 & 200 day moving average.
Should support at 6325 hold then the FTSE could make another push towards 6500.
Thursday’s session was quiet owing to most traders sitting on their hands given the Thanksgiving holiday in the US. Whilst the US markets are open for a half day, we’re not expecting much in the way of volume. Black Friday shopping is also offering another distraction.
European bourses are edging lower, as the vaccine optimism seen at the start of the week has completely fizzled now that questions are growing over the soundness of the AstraZeneca covid vaccine trial. The doubts could delay the cheap and easily transported vaccine from being approved quickly by regulators.
The pharmaceutical giant is likely to run a new additional study to assess the efficacy of a lower dosage after a subgroup which accidentally received an initial half dose revealed the dose to be 90% effective. AstraZeneca share are trading 1% lower.
Chinese factory profits soar
Concerns over the vaccine are overshadowing news that Chinese industrial profits surged at the fastest pace since early 2017. Although the minrers are finding support from the knowledge that the recovery in the world’s largest consumer of metals was powering along nicely. This is a stark contrast to Europe and the US which are still battling to bring covid infections under control.
Concerns over the vaccine are overshadowing news that Chinese industrial profits surged at the fastest pace since early 2017. Although the minrers are finding support from the knowledge that the recovery in the world’s largest consumer of metals was powering along nicely. This is a stark contrast to Europe and the US which are still battling to bring covid infections under control.
UK’s gloomy outlook
The British government yesterday announced the UK Tier breakdown for when the national lockdown ends next week. With around 20 million Brits going from national lockdown to Tier 3, the toughest category the economic outlook for the UK remains particularly gloomy
The British government yesterday announced the UK Tier breakdown for when the national lockdown ends next week. With around 20 million Brits going from national lockdown to Tier 3, the toughest category the economic outlook for the UK remains particularly gloomy
Oil & gold struggle
Oil prices are declining on Friday in quiet trade amid concerns over oversupply and doubts over a vaccine to end the covid pandemic. Despite falling for a second straight session both Brent and WTI are on track to book gains in the region of 6% across the week.
Meanwhile, the risk off mood wasn’t helping gold, which continues to struggle for direction just north of $1800.
Oil prices are declining on Friday in quiet trade amid concerns over oversupply and doubts over a vaccine to end the covid pandemic. Despite falling for a second straight session both Brent and WTI are on track to book gains in the region of 6% across the week.
Meanwhile, the risk off mood wasn’t helping gold, which continues to struggle for direction just north of $1800.
FTSE Chart
After the FTSE’s strong run up at the start of the month on vaccine news, the rally has been consolidating in the horizontal channel of 6515 and 6325. The price is currently find support on the lower ban of the channel. A break through 6325 could open the door to a deeper selloff towards horizontal support at 6120 and then near 6000, the confluence of the 50,100 & 200 day moving average.
Should support at 6325 hold then the FTSE could make another push towards 6500.
Related tags:
Latest market news
The complete CFD trading experience
Award-winning platforms, competitive spreads, low commissions and dedicated support.
We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
EUR/USD, FTSE 100 Forecast: Two trades to watch 1507
EUR/USD rises after weaker US CPI, PPI up next. FTSE 100 falls as weak China GDP data hits miners.
FTSE 100, USD/JPY Forecast: Two trades to watch
FTSE eases modestly despite inflation unexpectedly holding steady. USD/JPY drifts lower ahead of the FOMC rate decision.
EUR/USD, FTSE 100 Forecast: Two trades to watch 21-05-26
EUR/USD slips below 1.16 as weak eurozone data weighs on sentiment. FTSE 100 slips as oil prices rebound and caution returns.
StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.
StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.